Friday, 6 November 2026
M
Meridian Globe
Live briefing
Japan's trading house chiefs warn of uncertainty after US midterms— 日经 Nikkei AsiaJapan contractor's AI-guided tunnel boring outperforms human operators— 日经 Nikkei AsiaUS midterms live: Nasdaq tumbles 4% on AI regulation fears— 日经 Nikkei AsiaSony raises annual profit forecast on Spider-Man hit, gaming gains— 日经 Nikkei AsiaIndonesia's GDP grows 5.5% in Q3, helped by government spending— 日经 Nikkei AsiaToyota ready to 'regain market share' in China on expanded local sourcing— 日经 Nikkei AsiaTaiwan's chipmakers shine brightest in living memory— 日经 Nikkei AsiaAsian stock markets drop as Democratic win stokes fears over AI scrutiny— 日经 Nikkei AsiaJapan's trading house chiefs warn of uncertainty after US midterms— 日经 Nikkei AsiaJapan contractor's AI-guided tunnel boring outperforms human operators— 日经 Nikkei AsiaUS midterms live: Nasdaq tumbles 4% on AI regulation fears— 日经 Nikkei AsiaSony raises annual profit forecast on Spider-Man hit, gaming gains— 日经 Nikkei AsiaIndonesia's GDP grows 5.5% in Q3, helped by government spending— 日经 Nikkei AsiaToyota ready to 'regain market share' in China on expanded local sourcing— 日经 Nikkei AsiaTaiwan's chipmakers shine brightest in living memory— 日经 Nikkei AsiaAsian stock markets drop as Democratic win stokes fears over AI scrutiny— 日经 Nikkei Asia

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

Source Nature 生命科学2d ago
Summary

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Science
Region
Global
Language
English
Item ID
science-f81c0280

Comments 0 comments

No comments yet. Be the first.

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial · Meridian Globe